Suramin, patients with prostate cancer

Statins, see HMG Co-A reductase inhibitors Steroids, see Glucocorticoids Stimulants, in ADHD, 31.4 Sugammadex, 32.275 Sulfonamide derivatives, hypersensitivity reactions, 30.252 Sumatriptan, 17.171 Suprofen, nephrotoxicity, 12.88 Suramin, patients with prostate cancer, 20.283 Surgam, gastric reactions, 12.89 Suxamethonium, postoperative myalgia,... 

Meyer M, Jeong E, Bolinger B, Chen L, Lenehan P, Slichenmyer W, Natale RB. Phase 1 drug interaction study of suramin and warfarin in patients with prostate cancer. Am J Clin Oncol 2001 24(2) 167-71. 

Suramin has been combined with epirubicin in 26 patients with hormone-refractory prostate cancer (5). No additional therapeutic effect was found compared with... 

In a randomized study in 390 patients suramin has been given in a fixed low dose (3.192 g/m ), intermediate dose (5.320 g/m ), or high dose (7.661 g/m ) to determine whether its efficacy and toxicity in the treatment of patients with hormone-refractory prostate cancer is dose-dependent (8). There was no clear dose-response relation for survival or progression-free survival, but toxicity increased especially with the higher dose. There were neurological adverse effects in 40% of the patients and cardiac adverse effects in 15%. This raises questions about the usefulness of suramin, particularly in high doses, in advanced prostate cancer. However, in another... 

In 26 patients treated with suramin for hormone-refractory prostate cancer, furosemide reduced the total body clearance of suramin by 36% (37). In view of the increased risk of severe adverse effects after treatment with higher plasma concentrations of suramin, it would be... 

Falcone A, Antonuzzo A, Danes R, Allegrini G, Monica L, Planner E, Masi G, Ricci S, Del Tacca M, Conte P. Suramin in combination with weekly epirubicin for patients with advanced hormone-refractory prostate carcinoma. Cancer 1999 86(3) 470-6. 

Hussain M, Fisher El, Petrylak DP, O Connor J, Wood DP, Small EJ, Eisenberger MA, Crawford ED. Androgen deprivation and four courses of fixed-schedule suramin treatment in patients with newly diagnosed metastatic prostate cancer a Southwest Oncology Group Study. J CUn Oncol 2000 18(5) 1043-9. 

Calvo E, Cortes J, Rodriguez J, Sureda M, Beltran C, ReboUo J, Martinez-Monge R, Berian JM, de Irala J, Brugarolas A. Fixed higher dose schedule of suramin plus hydrocortisone in patients with hormone refractory prostate carcinoma a multicenter Phase II study. Cancer 2001 92(9) 2435 3. 

Small EJ, Halabi S, Ratain MJ, Rosner G, Stadler W, Palchak D, Marshall E, Rago R, Hars V, Wilding G, Petrylak D, Vogelzang NJ. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol 2002 20(16) 3369-75. 

Small EJ, Meyer M, Marshall ME, Reyno LM, Meyers FJ, Natale RB, Lenehan PF, Chen L, Slichenmyer WJ, Eisenberger M. Suramin therapy for patients with symptomatic hormone-refractory prostate cancer results of a randomized phase 111 trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. J Clin Oncol 2000 18(7) 1440-50. 

---